Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $918.43 million. The enterprise value is $613.19 million.
Important Dates
The next estimated earnings date is Thursday, July 31, 2025, after market close.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 69.68 million shares outstanding. The number of shares has increased by 6.11% in one year.
| Current Share Class | 69.68M |
| Shares Outstanding | 69.68M |
| Shares Change (YoY) | +6.11% |
| Shares Change (QoQ) | +0.68% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 60.21% |
| Float | 38.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.43 |
| Forward PS | 12.58 |
| PB Ratio | 2.76 |
| P/TBV Ratio | 2.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.71, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.71 |
| Quick Ratio | 4.45 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.80% and return on invested capital (ROIC) is -16.86%.
| Return on Equity (ROE) | -29.80% |
| Return on Assets (ROA) | -13.89% |
| Return on Invested Capital (ROIC) | -16.86% |
| Return on Capital Employed (ROCE) | -30.19% |
| Revenue Per Employee | $326,517 |
| Profits Per Employee | -$397,476 |
| Employee Count | 286 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zymeworks has paid $6.51 million in taxes.
| Income Tax | 6.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.50% in the last 52 weeks. The beta is 1.17, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +38.50% |
| 50-Day Moving Average | 11.78 |
| 200-Day Moving Average | 13.09 |
| Relative Strength Index (RSI) | 65.44 |
| Average Volume (20 Days) | 395,880 |
Short Selling Information
The latest short interest is 7.19 million, so 10.32% of the outstanding shares have been sold short.
| Short Interest | 7.19M |
| Short Previous Month | 6.79M |
| Short % of Shares Out | 10.32% |
| Short % of Float | 18.82% |
| Short Ratio (days to cover) | 15.91 |
Income Statement
In the last 12 months, Zymeworks had revenue of $93.38 million and -$113.68 million in losses. Loss per share was -$1.50.
| Revenue | 93.38M |
| Gross Profit | -46.11M |
| Operating Income | -108.81M |
| Pretax Income | -115.98M |
| Net Income | -113.68M |
| EBITDA | -99.29M |
| EBIT | -108.81M |
| Loss Per Share | -$1.50 |
Full Income StatementBalance Sheet
The company has $265.29 million in cash and $18.47 million in debt, giving a net cash position of $303.15 million or $4.35 per share.
| Cash & Cash Equivalents | 265.29M |
| Total Debt | 18.47M |
| Net Cash | 303.15M |
| Net Cash Per Share | $4.35 |
| Equity (Book Value) | 324.97M |
| Book Value Per Share | 4.67 |
| Working Capital | 241.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$75.78 million and capital expenditures -$1.82 million, giving a free cash flow of -$77.60 million.
| Operating Cash Flow | -75.78M |
| Capital Expenditures | -1.82M |
| Free Cash Flow | -77.60M |
| FCF Per Share | -$1.11 |
Full Cash Flow StatementMargins
Gross margin is -49.38%, with operating and profit margins of -116.52% and -121.73%.
| Gross Margin | -49.38% |
| Operating Margin | -116.52% |
| Pretax Margin | -114.77% |
| Profit Margin | -121.73% |
| EBITDA Margin | -106.33% |
| EBIT Margin | -116.52% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.11% |
| Shareholder Yield | -6.11% |
| Earnings Yield | -12.41% |
| FCF Yield | -8.47% |
Analyst Forecast
The average price target for Zymeworks is $19.50, which is 47.95% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.50 |
| Price Target Difference | 47.95% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 14.84% |
| EPS Growth Forecast (5Y) | -9.77% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 2.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.2 |
| Piotroski F-Score | 3 |